$3.94 Billion is the total value of Casdin Capital, LLC's 54 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVTA | INVITAE CORP | $411,630,000 | -11.7% | 12,203,669 | 0.0% | 10.45% | -24.8% | |
| BLFS | BIOLIFE SOLUTIONS INC | $331,159,000 | +23.6% | 7,440,107 | 0.0% | 8.41% | +5.4% | |
| FATE | FATE THERAPEUTICS INC | $295,086,000 | +5.3% | 3,400,000 | 0.0% | 7.49% | -10.3% | |
| EXAS | EXACT SCIENCES CORP | $293,395,000 | -5.7% | 2,360,186 | 0.0% | 7.45% | -19.6% | |
| VERV | New | VERVE THERAPEUTICS INC | $183,050,000 | – | 3,038,167 | +100.0% | 4.65% | – |
| PACB | PACIFIC BIOSCIENCES CALIF IN | $174,850,000 | +5.0% | 5,000,000 | 0.0% | 4.44% | -10.5% | |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $169,520,000 | +36.4% | 1,000,000 | +13.6% | 4.30% | +16.3% |
| BPMC | BLUEPRINT MEDICINES CORP | $136,338,000 | -9.5% | 1,550,000 | 0.0% | 3.46% | -22.9% | |
| TWST | TWIST BIOSCIENCE CORP | $133,250,000 | +7.6% | 1,000,000 | 0.0% | 3.38% | -8.3% | |
| DNLI | DENALI THERAPEUTICS INC | $126,288,000 | +37.4% | 1,610,000 | 0.0% | 3.21% | +17.1% | |
| RLAY | RELAY THERAPEUTICS INC | $123,493,000 | +5.8% | 3,375,058 | 0.0% | 3.14% | -9.8% | |
| AGIO | AGIOS PHARMACEUTICALS INC | $119,313,000 | +6.7% | 2,165,000 | 0.0% | 3.03% | -9.0% | |
| CDNA | CAREDX INC | $109,214,000 | +34.4% | 1,193,335 | 0.0% | 2.77% | +14.5% | |
| BEAM | BEAM THERAPEUTICS INC | $105,390,000 | +60.8% | 818,820 | 0.0% | 2.68% | +37.0% | |
| CDXS | CODEXIS INC | $98,118,000 | -1.0% | 4,330,000 | 0.0% | 2.49% | -15.6% | |
| IPSC | New | CENTURY THERAPEUTICS INC | $94,075,000 | – | 3,206,380 | +100.0% | 2.39% | – |
| OMIC | New | SINGULAR GENOMICS SYSTEMS IN | $74,000,000 | – | 2,692,870 | +100.0% | 1.88% | – |
| RVMD | Buy | REVOLUTION MEDICINES INC | $73,161,000 | -13.5% | 2,305,000 | +25.0% | 1.86% | -26.3% |
| DERMTECH INC | $72,540,000 | -18.2% | 1,745,000 | 0.0% | 1.84% | -30.3% | ||
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $68,800,000 | +67.8% | 885,000 | +60.9% | 1.75% | +43.0% |
| ADPT | Buy | ADAPTIVE BIOTECHNOLOGIES COR | $58,838,000 | +27.1% | 1,440,000 | +25.2% | 1.49% | +8.3% |
| BGNE | BEIGENE LTDsponsored adr | $51,479,000 | -1.4% | 150,000 | 0.0% | 1.31% | -15.9% | |
| AMRS | New | AMYRIS INC | $49,110,000 | – | 3,000,000 | +100.0% | 1.25% | – |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $45,876,000 | +25.1% | 1,310,000 | +45.6% | 1.16% | +6.7% |
| CNST | Sell | CONSTELLATION PHARMCETICLS I | $45,326,000 | +7.7% | 1,341,000 | -25.5% | 1.15% | -8.2% |
| GBIO | GENERATION BIO CO | $43,342,000 | -5.5% | 1,611,214 | 0.0% | 1.10% | -19.5% | |
| CRSP | CRISPR THERAPEUTICS AGnamen akt | $43,132,000 | +32.9% | 266,430 | 0.0% | 1.10% | +13.2% | |
| ALEC | ALECTOR INC | $34,370,000 | +3.4% | 1,650,000 | 0.0% | 0.87% | -11.9% | |
| ZLAB | ZAI LAB LTDadr | $33,628,000 | +32.6% | 190,000 | 0.0% | 0.85% | +13.1% | |
| MGTA | MAGENTA THERAPEUTICS INC | $32,724,000 | -17.4% | 3,346,034 | 0.0% | 0.83% | -29.6% | |
| ME | New | 23ANDME HOLDING CO | $32,048,000 | – | 2,741,457 | +100.0% | 0.81% | – |
| ALLO | Sell | ALLOGENE THERAPEUTICS INC | $31,948,000 | -30.4% | 1,225,000 | -5.8% | 0.81% | -40.7% |
| FDMT | Buy | 4D MOLECULAR THERAPEUTICS IN | $26,863,000 | -37.8% | 1,115,555 | +12.1% | 0.68% | -47.0% |
| NEO | New | NEOGENOMICS INC | $22,083,000 | – | 488,889 | +100.0% | 0.56% | – |
| GLUE | New | MONTE ROSA THERAPEUTICS INC | $21,812,000 | – | 960,883 | +100.0% | 0.55% | – |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $20,604,000 | -7.9% | 1,200,000 | +20.0% | 0.52% | -21.5% |
| RXRX | New | RECURSION PHARMACEUTICALS INcl a | $20,008,000 | – | 548,156 | +100.0% | 0.51% | – |
| MASS | 908 DEVICES INC | $15,752,000 | -20.1% | 406,502 | 0.0% | 0.40% | -31.9% | |
| ORTX | ORCHARD THERAPEUTICS PLCads | $14,116,000 | -39.5% | 3,215,434 | 0.0% | 0.36% | -48.5% | |
| KRON | KRONOS BIO INC | $13,973,000 | -18.2% | 583,436 | 0.0% | 0.36% | -30.3% | |
| FULC | Sell | FULCRUM THERAPEUTICS INC | $12,099,000 | -17.2% | 1,154,476 | -7.0% | 0.31% | -29.4% |
| ORIC | ORIC PHARMACEUTICALS INC | $10,641,000 | -27.8% | 601,515 | 0.0% | 0.27% | -38.5% | |
| DBTX | Buy | DECIBEL THERAPEUTICS INC | $10,074,000 | -22.6% | 1,171,421 | +2.2% | 0.26% | -34.0% |
| CLOV | CLOVER HEALTH INVESTMENTS CO | $9,677,000 | +76.2% | 726,511 | 0.0% | 0.25% | +50.0% | |
| BLI | BERKELEY LTS INC | $8,962,000 | -10.8% | 200,000 | 0.0% | 0.23% | -24.1% | |
| TKNO | New | ALPHA TEKNOVA INC | $7,119,000 | – | 300,000 | +100.0% | 0.18% | – |
| SGMO | SANGAMO THERAPEUTICS INC | $6,584,000 | -4.5% | 550,000 | 0.0% | 0.17% | -18.5% | |
| TPTX | TURNING POINT THERAPEUTICS I | $5,852,000 | -17.5% | 75,000 | 0.0% | 0.15% | -29.4% | |
| NAUT | New | NAUTILUS BIOTECHNOLOGY INC | $5,050,000 | – | 500,000 | +100.0% | 0.13% | – |
| SEER | SEER INC | $4,917,000 | -34.5% | 150,000 | 0.0% | 0.12% | -43.9% | |
| STOK | STOKE THERAPEUTICS INC | $4,039,000 | -13.3% | 120,000 | 0.0% | 0.10% | -25.9% | |
| FHTX | FOGHORN THERAPEUTICS INC | $2,307,000 | -19.1% | 216,216 | 0.0% | 0.06% | -30.6% | |
| ZY | New | ZYMERGEN INC | $1,200,000 | – | 30,000 | +100.0% | 0.03% | – |
| SANA | SANA BIOTECHNOLOGY INC | $1,180,000 | -41.2% | 60,000 | 0.0% | 0.03% | -50.0% | |
| CDAK | Exit | CODIAK BIOSCIENCES INC | $0 | – | -76,688 | -100.0% | -0.03% | – |
| DYN | Exit | DYNE THERAPEUTICS INC | $0 | – | -610,000 | -100.0% | -0.28% | – |
| TSHA | Exit | TAYSHA GENE THERAPIES INC | $0 | – | -820,440 | -100.0% | -0.50% | – |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -2,211,622 | -100.0% | -0.65% | – |
| BNR | Exit | BURNING ROCK BIOTECH LTDsponsored adr | $0 | – | -847,150 | -100.0% | -0.68% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.